Alterity Financial Group LLC Decreases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Alterity Financial Group LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,531 shares of the medical research company’s stock after selling 19 shares during the quarter. Thermo Fisher Scientific makes up approximately 3.4% of Alterity Financial Group LLC’s portfolio, making the stock its 5th biggest position. Alterity Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $2,405,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Halpern Financial Inc. increased its stake in shares of Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after buying an additional 40 shares during the period. Coppell Advisory Solutions LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter worth about $33,000. Live Oak Investment Partners bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $36,000. Tyler Stone Wealth Management bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $37,000. Finally, Indiana Trust & Investment Management CO acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HSBC started coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 price target on the stock. Raymond James increased their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Royal Bank of Canada raised their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Finally, TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $599.00.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $581.21 on Friday. The firm has a market cap of $221.62 billion, a price-to-earnings ratio of 37.62, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80. The stock has a fifty day simple moving average of $565.13 and a two-hundred day simple moving average of $520.22. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.40 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last 90 days. 0.32% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.